Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 7:25 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 245 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Needle-Syringe Clear all

Conditions: Hypereosinophilic Syndrome
Interventions: dupilumab; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Fecal Incontinence
Interventions: NASHA/Dx (Solesta) Gel, Sham Injection; Device
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 8
States / cities: San Francisco, California • Tampa, Florida • Burlington, Massachusetts + 5 more

Conditions: Germ Cell Tumor
Interventions: Bleomycin (active name: Bleomycin Sulfate), Etoposide, Cisplatin, Pegylated G-CSF (Pegfilgrastim), Filgrastim; Drug
Lead sponsor: University of Sydney; Other
Eligibility: 11 Years to 50 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2029
U.S. locations: 21
States / cities: Downey, California • Loma Linda, California • Long Beach, California + 15 more

Conditions: Psoriasis, Aging, Epigenetic Disorder, Inflammation; Skin
Interventions: TILDRAKIZUMAB; Biological
Lead sponsor: Carlos Wambier; Other
Eligibility: 35 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Pain, Postoperative, Shoulder Osteoarthritis
Interventions: local infiltration of liposomal bupivacaine, continuous infusion of ropivacaine interscalene nerve block; Drug · Other
Lead sponsor: TriHealth Inc.; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Verification of Needle Tip Placement in the Lumbar Epidural Space
Interventions: Active: Comparator Loss Of Resistance Syringe, Experimental: CompuFlo® Epidural System; Device
Lead sponsor: Milestone Scientific, Inc; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 5
States / cities: Irvine, California • Rancho Mirage, California • San Diego, California + 2 more

Conditions: Diabetic Macular Edema
Interventions: Faricimab, Sham Procedure; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1,479 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 119
States / cities: Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 105 more

Conditions: Knee Injury
Interventions: J-Tip, Syringe and 25 gauge needle; Device
Lead sponsor: Orlando Health, Inc.; Other
Eligibility: 11 Years to 17 Years
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Alcohol Use Disorder
Interventions: Exenatide, Sham injection; Drug · Other
Lead sponsor: Boston Medical Center; Other
Eligibility: 21 Years to 55 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Urethral Stricture
Interventions: Clostridium Histolyticum Collagenase, Saline; Drug · Other
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older · Male only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Mediastinal Lymphadenopathy, Lung Malignancies
Interventions: Endobronchial Ultrasound; Procedure
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Staten Island, New York

Conditions: Wet Macular Degeneration
Interventions: Faricimab, Aflibercept, Sham Procedure; Drug · Procedure
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 50 Years and older
Enrollment: 671 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 52
States / cities: Phoenix, Arizona • Tucson, Arizona • Campbell, California + 47 more

Conditions: Healthy Volunteers
Interventions: Vedolizumab SC; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Obesity, Type 2 Diabetes Mellitus
Interventions: MCT oil hypocaloric liquid diet, LCT hypocaloric liquid diet, Subcutaneous abdominal adipose tissue biopsy; Behavioral · Procedure
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Food Allergy, Anaphylaxis, Food Hypersensitivity, Food Allergy Peanut
Interventions: Epinephrine Auto-Injector 0.3 mg/0.3 mL, Epinephrine 0.3 mg intramuscular manual injection via a syringe and needle, IN-001 9.06 mg Sublingual Spray, IN-001 13.59 mg Sublingual Spray; Drug
Lead sponsor: Insignis Therapeutics, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Trauma, Trauma Injury, Pain, Acute
Interventions: Bupivacaine Liposome Injection, Bupivacaine; Drug
Lead sponsor: Chadrick Evans; Other
Eligibility: 18 Years and older
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Peoria, Illinois

Conditions: Meniere's Disease
Interventions: Magnevist (gadopentetate dimeglumine); Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: San Diego, California

Conditions: Skin Quality
Interventions: Hyper-Diluted Botox, Topical anesthesia, 0.9% saline solution; Drug · Other
Lead sponsor: Steve Yoelin M.D. Medical Associates, Inc.; Other
Eligibility: 35 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Head and Neck Cancer, Surgery--Complications, Graft Failure
Interventions: Tumescence During STSG Harvest; Procedure
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Healthy Adults
Interventions: LectraJet, TIV by jet injection, Seasonal Trivalent Influenza Vaccine; Device · Biological
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 49 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: College Park, Maryland

Conditions: Smallpox
Interventions: MVA Smallpox Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 435 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 6
States / cities: Decatur, Georgia • Iowa City, Iowa • Baltimore, Maryland + 3 more

Conditions: Diabetic Retinopathy
Interventions: Tarcocimab, Sham injection; Drug · Other
Lead sponsor: Kodiak Sciences Inc; Industry
Eligibility: 18 Years and older
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 38
States / cities: Tucson, Arizona • Fullerton, California • Glendale, California + 34 more

Conditions: Breast Cancer, Healthy, no Evidence of Disease
Interventions: Random fine need aspiration (rFNA), Mammogram; Procedure · Other
Lead sponsor: Northwestern University; Other
Eligibility: 35 Years to 60 Years · Female only
Enrollment: 385 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Femoral Neck Fractures, Hip Fractures
Interventions: Femoral nerve block: 25 mL of 0.5% bupivacaine, Placebo: 3cc of 0.9% Normal Saline; Drug
Lead sponsor: Rhode Island Hospital; Other
Eligibility: 55 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Providence, Rhode Island

Search by objective public record fields.

Dupilumab as Add-On Therapy for Hypereosinophilic Syndrome With Partial Clinical Response to Eosinophil-Depleting Biologic Agents

A Randomized, Blinded, Multicenter Study to Evaluate NASHA/Dx for the Treatment of Fecal Incontinence

Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours

Effects of Tildrakizumab on Epigenetic Age

Effective Pain Management During Shoulder Replacement Surgery With EXPAREL

CompuFlo® Assessment Study for the Epidural Space Verification

A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema

Needleless Jet Injected (J-Tip) Lidocaine in Children Undergoing Regional Anesthesia Prior to Knee Arthroscopy

The Effects of Exenatide, a GLP-1 Agonist, on Alcohol Self-Administration in Heavy Drinkers

Clostridium Histolyticum Collagenase Injection for Urethral Disease

Endobronchial Ultrasound Transbronchial Needle Aspiration Using Needle Suction Versus No Suction

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)

A Pilot Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Needle Safety Device (PFS+NSD) in Healthy Participants

Use of MCT Oil for Enhancement of Weight Loss and Glycemic Control in Obese Diabetic Patients

PK/PD Study of IN-001 Sublingual Spray in Healthy Adults

Liposomal Bupivacaine Intercostal Nerve Block vs Thoracic Epidural for Regional Analgesia in Multiple Rib Fractures

Magnetic Resonance Imaging Evaluation of Inner Ear Pathology Using Intra-Tympanic Contrast Agent

Evaluation of Skin Quality Improvement

Tumescence in HNC Skin Graft Reconstruction

Safety Study of Seasonal Influenza Vaccine by Jet Injection

Phase II Trial to Assess Safety and Immunogenicity of IMVAMUNE®

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)

Study of Breast Tissue in Women Not Previously Diagnosed With Breast Cancer Who Are Undergoing Fine Needle Aspiration

Ultrasound-guided Femoral Nerve Blocks in Elderly Patients With Hip Fractures